Ryan M. Teague, Ph.D., CLIP InvestigatorSaint Louis University School of Medicine

Research in our lab is revealing how factors such as age and obesity impact the risks and rewards of immunotherapy.
Area of Research: All Cancers

Checkpoint immunotherapies targeting the CTLA-4 and PD-1 pathways have been approved for several cancers and have helped many patients. When they’re used together, they can work even better because they target non-redundant pathways. There are other checkpoints as well, including LAG-3, which Dr. Teague is targeting, alone and with anti-CTLA-4 and anti-PD-1 immunotherapies. Altogether, he’s testing 8 different combinations to see which work best. He’s also characterizing the activity of different pathways under each of these conditions, to see how they influence outcomes. This will hopefully provide doctors with clues about which combinations might work well in humans as well as provide biomarkers to predict which patients are more likely to respond.

Projects and Grants

Defining the mechanisms of human T cell rescue by checkpoint blockade immunotherapy

Saint Louis University School of Medicine | All Cancers | 2014

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top